Condition: Acute Stroke · Sponsor: National Society for Neurosonology and Cerebral Circulation
The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.
This description comes directly from the study's public registry record.
Tatiana Kharitonova · +79217450431 · tvh2001@mail.ru
Always discuss trial participation with your own doctor first.
| St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze | Saint Petersburg, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05697575